We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.25 | -1.19% | 20.75 | 20.00 | 21.50 | 21.50 | 20.25 | 21.00 | 453,566 | 14:00:03 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 7.31 | 18.92M |
Date | Subject | Author | Discuss |
---|---|---|---|
22/1/2018 15:58 | Elrico - yeah I can respect that. Only thing is, with that in mind, we could easily be waiting till 2020, who knows - not like we can be told anything. | loungeact | |
22/1/2018 15:43 | "Sarah Vine writing in the Mail yesterday about her ongoing weight loss said her blood pressure is staying far too high." If her blood pressure is high she must be reading the Mail as well as writing for it, that's her mistake. | runthejoules | |
22/1/2018 14:40 | I thought I had found you an update on Slimbiome from yesterday:- “Netherlands-b Sadly it was posted two years ago yesterday. hxxps://www.dairyrep Guess the fast track was not that fast. Still, it’s in Gofigure. | imnotlong | |
22/1/2018 14:39 | Loungeact - You have a point. However, as unfair as it may seem to us PI's, the partners have a big say on what and when can info can disclosed. It took several months for OPTI to be given permission to use TATA's name in a non official capacity. OPTI's very small team are better utilised negotiating commercial agreements and closing them out rather than seeking permission to disclose snippets at the risk of alerting partners competitors of their next commercial strategic move in a very competitive environment. | elrico | |
22/1/2018 13:15 | Ferdy - The time for a more comprehensive update will be FY results sometime near the back end of April. | elrico | |
22/1/2018 12:38 | I think...SOH has said he doesn't intend to give running commentary, which I can understand. But there needs to be some middle ground between running commentary and complete radio silence on a specific agreement/project and it's current state. | loungeact | |
22/1/2018 12:11 | Yes, I think a comprehensive update on each area of the business is desperately needed. What has happened to all the agreements we got a couple of years ago? Slimfast anyone? Much more clarity needed in my view! | f3rdinand | |
22/1/2018 10:01 | Sweetbiotix commercialisation in 2016/2017. Tata slimbiome products launched in 2017. It's great for a company to begin new projects and continue researching/discover | loungeact | |
22/1/2018 09:56 | Anyone know if HSR sent round an update following the last company RNS? | colinzeal | |
22/1/2018 09:42 | Some of it's built, but the good thing about us is that in years to come we will still be building , albeit even more new discoveries to help health, to help with the share price we badly need projections on profits, the only thing the market seems to make notice of, then see us rocket. DIAMOND. | diamond fibre | |
22/1/2018 08:52 | 5 Billion things being worked on....in the background. | loungeact | |
22/1/2018 08:04 | Indeed, sugar-free aka Sweetbiotix;0) | trotterstrading | |
21/1/2018 19:25 | Shot in the dark and not sure if the last sentence is related to Opti “Knighton Foods currently offer milk, dark and white chocolate but the process can convert any chocolate into a powder so the opportunities are endless. We have an off-the-shelf range, which makes MOQs of 25kg achievable but equally we offer bespoke solutions. We are also currently working on reduced sugar products and a sugar-free product. Come on Angus, let’s have a look around!” | zebbo | |
21/1/2018 19:00 | Well, we have the GM on the 25 Jan and ProBiota 2018 in Barcelona from 7-9 February 2018. Interesting if we get another RNS or 2 :-) | zebbo | |
21/1/2018 18:14 | Diamond It's built. We can see the distance what looks like an army coming.... S | shrewdmole | |
21/1/2018 14:07 | I have said this in the past, When we build it they will come. DIAMOND | diamond fibre | |
21/1/2018 14:07 | I have said this in the past, When we build it they will come. DIAMOND | diamond fibre | |
21/1/2018 13:08 | Agree with Shrewd there - It would be good for Opti to update their progress chart that's on the website. It's quite hard to keep up where they are with each product/deal etc. A good problem to have really. | loungeact | |
21/1/2018 12:33 | Both Chr Hansen and DSM will have signed off the recent RNS. So, IMHO there is more to this than is disclosed in the RNS. It is not just my opinion, we are almost at the commercial tipping point, where revenues may not be required for the wider market to grasp the multiple global opportunities here. | elrico | |
21/1/2018 11:52 | Guys Just a thought would dsm want it in the public domain about how Opti have improved things if they hadn't already done some kind of deal? I can't see it myself. Wonder if probiota will be the day of the commercial Rns? It is actually hard to keep up now with all the progress on all the fronts here. Almost need a spreadsheet! S | shrewdmole | |
21/1/2018 11:41 | Some great posts. Thank parob, elric, shrewdmole. Thankfully, i was aware of the importance of the optibiotic platform because my friend explained it to me last year. What we really have is multiple opportunities on the sugar front with sweetbiotix and optibiotic. So looking forward to my belgium chocolates not making me feel guilty as a troff through a box. And those lovely greek yogurt marketed as fat free but the calorie kill the waistline because the calories do the real damage, but now have sweetbiotix and slimbiome in them. And to think i won't need to hide the yogurt behind the milk to avoid temptation at binging on the second. Hey, no comment from tw either after the recent rns. I guess he has not worked out the significance yet. Send him an email boys. Second thoughts, don't. | incanus | |
21/1/2018 11:33 | I am sure the enhancing effect is excellent. Why else would OPTI win the best abstract award. | parob | |
21/1/2018 11:29 | Animal feed was discussed on this bb about 2 years ago! That is another huge market in it's own right.I'm sure I'm not the only one who is looking forward to learning of the actual 'enhancing' effect. Just over 2 weeks to go unless we find out before Probiota. | parob | |
21/1/2018 11:16 | OptiBiotic platform is a huge commercial beast in its own right because it opens up a whole new commercial market for OPTI it otherwise would not be able to touch die to patent protections, etc. Now OPTI could be the one to go to breath new live into tired probiotic brands. Parob identifies a number of potential area's, companies OptiBiotic could enhance existing probiotics. The abstract/talk next month will ensure the decision makers in the probiotic arena will sit up and note, especially given the involvement of Chr Hansen and DSM. These are key players here, it guarantees a respected audience and will encourage others to follow. | elrico |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions